Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cell cycle regulation by anticancer agent]

T Nomoto1, K Nishio, N Saijo

  • 1Pharmacology Division, National Cancer Center Research Institute, Tokyo.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Direct observation of the superallowed α-decay of <sup>104</sup>Te.

Nature·2026
Same author

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.

ESMO open·2023
Same author

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR).

ESMO open·2022
Same author

Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Simultaneous Determination of Neutron-Induced Fission and Radiative Capture Cross Sections from Decay Probabilities Obtained with a Surrogate Reaction.

Physical review letters·2020
Same author

Study of Quasielastic Barrier Distributions as a Step towards the Synthesis of Superheavy Elements with Hot Fusion Reactions.

Physical review letters·2020

Certain anticancer drugs halt cell division by targeting cell cycle regulators like cyclin-dependent kinases (CDKs). Cisplatin, for example, may induce G2-phase arrest via cdc2 kinase dephosphorylation, impacting cancer treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Context:

  • Anticancer agents are crucial in cancer therapy.
  • Understanding their mechanisms of action, particularly cell cycle regulation, is vital for developing effective treatments.
  • Specific agents target distinct phases of the cell cycle.

Purpose:

  • To investigate the effects of various anticancer agents on cell cycle regulators.
  • To elucidate the molecular mechanisms by which these agents induce cell cycle arrest and apoptosis.
  • To identify key kinases involved in drug-induced cell cycle modulation.

Summary:

  • This study analyzes how anticancer drugs affect cell cycle regulators, focusing on cyclin-dependent kinases (CDKs).
  • Cisplatin appears to induce G2-phase arrest by regulating cdc2 kinase dephosphorylation.

Related Experiment Videos

  • Butyrolactone I, paclitaxel, suramin, and UCN-01 exhibit distinct effects on cell cycle progression and kinase inhibition, with some also inducing apoptosis.

    • Impact:

    • Provides insights into the cell cycle-specific mechanisms of action for several anticancer agents.
    • Highlights the role of cdc2 and CDK2 kinases in mediating drug responses.
    • Contributes to the rational design of novel anticancer therapies targeting cell cycle pathways.